Company intelligence / Profile preview
InnoSkel
Nice, Provence-Alpes-Côte d'Azur, Franceinnoskel.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
InnoSkel’s lead asset, INS101, a gene therapy targeting type II collagen disorders such as spondyloepiphyseal dysplasia congenita, has shown strong efficacy in preclinical proof-of-concept studies. The company was awarded an Innovation Passport by the UK MHRA to accelerate development and access for its first-in-class treatment. No clinical trial results are available yet.
- Therapeutic areas
- Rare Diseases
- Modalities
- Gene therapy
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on InnoSkel.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on InnoSkel.